Title : Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes - Herman_2006_Curr.Med.Res.Opin_22_1939 |
Author(s) : Herman GA , Bergman A , Yi B , Kipnes M |
Ref : Curr Med Res Opin , 22 :1939 , 2006 |
Abstract :
OBJECTIVE: As part of the clinical development of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes, the potential for pharmacokinetic interactions with other antihyperglycemic agents used in managing patients with type 2 diabetes are being carefully evaluated. The purposes of this study were to evaluate the tolerability of co-administered sitagliptin and metformin and effects of sitagliptin on metformin pharmacokinetics as well as metformin on sitagliptin pharmacokinetics under steady-state conditions. |
PubMedSearch : Herman_2006_Curr.Med.Res.Opin_22_1939 |
PubMedID: 17022853 |
Inhibitor | Sitagliptin |
Herman GA, Bergman A, Yi B, Kipnes M (2006)
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
Curr Med Res Opin
22 :1939
Herman GA, Bergman A, Yi B, Kipnes M (2006)
Curr Med Res Opin
22 :1939